Polymer-controlled release of tobramycin from bone graft void filler

Drug Delivery and Translational Research

Volumn 3, Issue 6, 2013, Pages 518-530

  Brooks, Amanda E ^a   Brooks, Benjamin D ^a   Davidoff, Sherry N ^c   Hogrebe, Paul C ^c   Fisher, Mark A ^b   Grainger, David W ^a,c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c University of Utah   (United States)

Author keywords

Allograft bone; Controlled release; Implant infection; Polycaprolactone; Tobramycin

Indexed keywords

ANTIBIOTIC AGENT; BIOMATERIAL; MACROGOL; POLYCAPROLACTONE; POLYMER; ROSEOLIC ACID; TOBRAMYCIN;

ARTICLE; BIOLOGICAL ACTIVITY; BONE ALLOGRAFT; BONE FILLER; BONE GRAFT; CERAMICS; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFECTION; MICROBIOLOGY; OSSIFICATION; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL;

EID: 84887181721     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-013-0155-x     Document Type: Article

References (85)

1. Conterno LO, da Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev. 2009;3, CD004439.
2. Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sorgel F. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet. 2009;48(2): 89-124.
3. Bernthal NM, Stavrakis AI, Billi F, Cho JS, Kremen TJ, Simon SI, et al. A mouse model of post-arthroplasty Staphylococcus aureus joint infection to evaluate in vivo the efficacy of antimicrobial implant coatings. PLoS One. 2010;5(9): e12580.
4. Merrill C, Elixhauser A. Hospital stays involving musculoskeletal procedures, 1997-2005. HCUP Statistical Brief #34; 2007.
5. Jiranek WA, Hanssen AD, Greenwald AS. Antibiotic-loaded bone cement for infection prophylaxis in total joint replacement. J Bone Joint Surg Am. 2006;88(11): 2487-500.
6. Kalorama Information Market Intelligence Report. Orthopedic biomaterials: World Market, September 2007.
7. Vasilev K, Cook J, Griesser HJ. Antibacterial surfaces for biomedical devices. Expert Rev Med Devices. 2009;6(5): 553-67.
8. Reichert JC, Saifzadeh S, Wullschleger ME, Epari DR, Schutz MA, Duda GN, et al. The challenge of establishing preclinical models for segmental bone defect research. Biomaterials. 2009;30(12): 2149-63.
9. Oest ME, Dupont KM, Kong HJ, Mooney DJ, Guldberg RE. Quantitative assessment of scaffold and growth factor-mediated repair of critically sized bone defects. J Orthop Res. 2007;25(7): 941-50.
10. Giannoudis PV, Dinopoulos H, Tsiridis E. Bone substitutes: an update. Injury. 2005;36 Suppl 3: S20-7.
11. Bostrom MP, Seigerman DA. The clinical use of allografts, demineralized bone matrices, synthetic bone graft substitutes and osteoinductive growth factors: a survey study. HSS J. 2005;1(1): 9-18.
12. Parikh SN. Bone graft substitutes: past, present, future. J Postgrad Med. 2002;48(2): 142-8.
13. McLaren AC. Alternative materials to acrylic bone cement for delivery of depot antibiotics in orthopaedic infections. Clin Orthop Relat Res. 2004;427: 101-6.
14. Costerton J. The etiology and persistence of cryptic bacterial infection: a hypothesis. Rev Infect Dis. 1984;6: 608-16.
15. Nandi SK, Roy S, Mukherjee P, Kundu B, De DK, Basu D. Orthopaedic applications of bone graft & graft substitutes: a review. Indian J Med Res. 2010;132: 15-30.
16. McKee MD, Wild LM, Schemitsch EH, Waddell JP. The use of an antibiotic-impregnated, osteoconductive, bioabsorbable bone substitute in the treatment of infected long bone defects: early results of a prospective trial. J Orthop Trauma. 2002;16(9): 622-7.
17. Koort JK, Makinen TJ, Suokas E, Veiranto M, Jalava J, Tormala P, et al. Sustained release of ciprofloxacin from an osteoconductive poly(dl)-lactide implant. Acta Orthop. 2008;79(2): 295-301.
18. Koort JK, Suokas E, Veiranto M, Makinen TJ, Jalava J, Tormala P, et al. In vitro and in vivo testing of bioabsorbable antibiotic containing bone filler for osteomyelitis treatment. J Biomed Mater Res A. 2006;78(3): 532-40.
19. Kanellakopoulou K, Giamarellos-Bourboulis EJ. Carrier systems for the local delivery of antibiotics in bone infections. Drugs. 2000;59(6): 1223-32.
20. Winkler H, Stoiber A, Kaudela K, Winter F, Menschik F. One stage uncemented revision of infected total hip replacement using cancellous allograft bone impregnated with antibiotics. J Bone Joint Surg Br. 2008;90(12): 1580-4.
21. Beaman FD, Bancroft LW, Peterson JJ, Kransdorf MJ, Menke DM, DeOrio JK. Imaging characteristics of bone graft materials. Radiographics. 2006;26(2): 373-88.
22. Borkhuu B, Borowski A, Shah SA, Littleton AG, Dabney KW, Miller F. Antibiotic-loaded allograft decreases the rate of acute deep wound infection after spinal fusion in cerebral palsy. Spine (Phila Pa 1976). 2008;33(21): 2300-4.
23. Buttaro M, Comba F, Piccaluga F. Vancomycin-supplemented cancellous bone allografts in hip revision surgery. Clin Orthop Relat Res. 2007;461: 74-80.
24. Buttaro MA, Gonzalez Della Valle AM, Pineiro L, Mocetti E, Morandi AA, Piccaluga F. Incorporation of vancomycin-supplemented bone incorporation of vancomycin-supplemented bone allografts: radiographical, histopathological and immunohistochemical study in pigs. Acta Orthop Scand. 2003;74(5): 505-13.
25. Buttaro MA, Morandi A, Rivello HG, Piccaluga F. Histology of vancomycin-supplemented impacted bone allografts in revision total hip arthroplasty. J Bone Joint Surg Br. 2005;87(12): 1684-7.
26. Day RE, Megson S, Wood D. Iontophoresis as a means of delivering antibiotics into allograft bone. J Bone Joint Surg Br. 2005;87(11): 1568-74.
27. Finley JM. Antibiotic supplementation of bone allografts: a review. J West Soc Periodontol Periodontal Abstr. 2001;49(1): 5-9.
28. Harris RJ. A clinical evaluation of an allograft combined with a bioabsorbable membrane versus an alloplast/allograft composite graft combined with a bioabsorbable membrane. 100 consecutively treated cases. J Periodontol. 1998;69(5): 536-46.
29. Kanellakopoulou K, Sahinides T, Tsaganos T, Galanakis N, Giamarellou H, Giamarellos-Bourboulis EJ. In vitro release of fusidic acid and teicoplanin from cancellous bone allografts. J Chemother. 2008;20(5): 645-7.
30. Petri 3rd WH, Wilson TM. Clinical evaluation of antibiotic-supplemented bone allograft. J Oral Maxillofac Surg. 1993;51(9): 982-5. discussion 6.
31. Whiteside LA. Treatment of infected total knee arthroplasty. Clin Orthop Relat Res. 1994;299: 169-72.
32. Winkler H, Kaudela K, Stoiber A, Menschik F. Bone grafts impregnated with antibiotics as a tool for treating infected implants in orthopedic surgery-one stage revision results. Cell Tissue Bank. 2006;7(4): 319-23.
33. Witso E, Persen L, Benum P, Bergh K. Cortical allograft as a vehicle for antibiotic delivery. Acta Orthop. 2005;76(4): 481-6.
34. Witso E, Persen L, Loseth K, Bergh K. Adsorption and release of antibiotics from morselized cancellous bone. In vitro studies of 8 antibiotics. Acta Orthop Scand. 1999;70(3): 298-304.
35. Ketonis C, Adams CS, Barr S, Aiyer A, Shapiro IM, Parvizi J, et al. Antibiotic modification of native grafts: improving upon nature's scaffolds. Tissue Eng Part A. 2010;16(6): 2041-9.
36. Ketonis C, Barr S, Adams CS, Hickok NJ, Parvizi J. Bacterial colonization of bone allografts: establishment and effects of antibiotics. Clin Orthop Relat Res. 2010;468(8): 2113-21.
37. Ketonis C, Barr S, Adams CS, Shapiro IM, Parvizi J, Hickok NJ. Vancomycin bonded to bone grafts prevents bacterial colonization. Antimicrob Agents Chemother. 2011;55(2): 487-94.
38. Ketonis C, Barr S, Shapiro IM, Parvizi J, Adams CS, Hickok NJ. Antibacterial activity of bone allografts: comparison of a new vancomycin-tethered allograft with allograft loaded with adsorbed vancomycin. Bone. 2011;48(3): 631-8.
39. Mathijssen NM, Petit PL, Pilot P, Schreurs BW, Buma P, Bloem RM. Impregnation of bone chips with antibiotics and storage of antibiotics at different temperatures: an in vitro study. BMC Musculoskelet Disord. 2010;11: 96.
40. Witso E, Persen L, Benum P, Bergh K. Release of netilmicin and vancomycin from cancellous bone. Acta Orthop Scand. 2002;73(2): 199-205.
41. Witso E, Persen L, Loseth K, Benum P, Bergh K. Cancellous bone as an antibiotic carrier. Acta Orthop Scand. 2000;71(1): 80-4.
42. Diefenbeck M, Muckley T, Hofmann GO. Prophylaxis and treatment of implant-related infections by local application of antibiotics. Injury. 2006;37 Suppl 2: S95-S104.
43. Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? Postgrad Med J. 2000;76(898): 479-83.
44. Levin PD. The effectiveness of various antibiotics in methyl methacrylate. J Bone Joint Surg Br. 1975;57(2): 234-7.
45. Miclau T, Dahners LE, Lindsey RW. In vitro pharmacokinetics of antibiotic release from locally implantable materials. J Orthop Res. 1993;11(5): 627-32.
46. Chen CE, Ko JY, Pan CC. Results of vancomycin-impregnated cancellous bone grafting for infected tibial nonunion. Arch Orthop Trauma Surg. 2005;125(6): 369-75.
47. Communication OotADf. CDC urges hospitals and healthcare facilities to increase efforts to reduce drug-resistant infections. 2006. http://www. cdc. gov/media/pressrel/r061019. htm?s_cid=mediarel_r061019_x. Accessed 23 June 2011.
48. Patzakis MJ, Zalavras CG. Chronic posttraumatic osteomyelitis and infected nonunion of the tibia: current management concepts. J Am Acad Orthop Surg. 2005;13(6): 417-27.
49. Lowry KJ, Hamson KR, Bear L, Peng YB, Calaluce R, Evans ML, et al. Polycaprolactone/glass bioabsorbable implant in a rabbit humerus fracture model. J Biomed Mater Res. 1997;36(4): 536-41.
50. Coombes AG, Rizzi SC, Williamson M, Barralet JE, Downes S, Wallace WA. Precipitation casting of polycaprolactone for applications in tissue engineering and drug delivery. Biomaterials. 2004;25(2): 315-25.
51. Chang HI, Perrie Y, Coombes AG. Delivery of the antibiotic gentamicin sulphate from precipitation cast matrices of polycaprolactone. J Control Release. 2006;110(2): 414-21.
52. Lam CX, Savalani MM, Teoh SH, Hutmacher DW. Dynamics of in vitro polymer degradation of polycaprolactone-based scaffolds: accelerated versus simulated physiological conditions. Biomed Mater. 2008;3(3): 034108.
53. Hutmacher DW, Schantz JT, Lam CX, Tan KC, Lim TC. State of the art and future directions of scaffold-based bone engineering from a biomaterials perspective. J Tissue Eng Regen Med. 2007;1(4): 245-60.
54. Wei X, Gong C, Gou M, Fu S, Guo Q, Shi S, et al. Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int J Pharm. 2009;381(1): 1-18.
55. Sevy JO, Slawson MH, Grainger DW, Brooks AE. Assay method for polymer-controlled antibiotic release from allograft bone to target orthopaedic infections. Biomed Sci Instrum. 2010;46: 136-41.
56. Darley ES, MacGowan AP. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother. 2004;53(6): 928-35.
57. Rhyu KH, Jung MH, Yoo JJ, Lee MC, Seong SC, Kim HJ. In vitro release of vancomycin from vancomycin-loaded blood coated demineralised bone. Int Orthop. 2003;27(1): 53-5.
58. Winkler H, Janata O, Berger C, Wein W, Georgopoulos A. In vitro release of vancomycin and tobramycin from impregnated human and bovine bone grafts. J Antimicrob Chemother. 2000;46(3): 423-8.
59. Witso E, Persen L, Benum P, Aamodt A, Husby OS, Bergh K. High local concentrations without systemic adverse effects after impaction of netilmicin-impregnated bone. Acta Orthop Scand. 2004;75(3): 339-46.
60. Lindsey RW, Probe R, Miclau T, Alexander JW, Perren SM. The effects of antibiotic-impregnated autogeneic cancellous bone graft on bone healing. Clin Orthop Relat Res. 1993;291: 303-12.
61. Wu P, Grainger DW. Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials. 2006;27(11): 2450-67.
62. Dunnett C, Goldsmith C. When and how to do multiple comparisons. In: Buncher CR, Tsay J-Y, editors. Statistics in the pharmaceutical industry. 3rd ed. New York: Chapman and Hall; 2006. p. 421-52.
63. Begg EJ, Barclay ML. Aminoglycosides-50 years on. Br J Clin Pharmacol. 1995;39(6): 597-603.
64. Gogia JS, Meehan JP, Di Cesare PE, Jamali AA. Local antibiotic therapy in osteomyelitis. Semin Plast Surg. 2009;23(2): 100-7.
65. Antoci Jr V, Adams CS, Hickok NJ, Shapiro IM, Parvizi J. Antibiotics for local delivery systems cause skeletal cell toxicity in vitro. Clin Orthop Relat Res. 2007;462: 200-6.
66. Davidoff SN, Call BP, Hogrebe PC, Grainger DW, Brooks AE. A robust method to coat allograft bone with a drug-releasing polymer shell. Biomed Sci Instrum. 2010;46: 184-9.
67. Koort JK, Makinen TJ, Suokas E, Veiranto M, Jalava J, Knuuti J, et al. Efficacy of ciprofloxacin-releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49(4): 1502-8.
68. Mousset B, Benoit MA, Delloye C, Bouillet R, Gillard J. Biodegradable implants for potential use in bone infection. An in vitro study of antibiotic-loaded calcium sulphate. Int Orthop. 1995;19(3): 157-61.
69. Brandl M, Gu L. Degradation of tobramycin in aqueous solution. Drug Development and Industrial Pharmacy. 1992;18(13): 1423-36.
70. Davidoff SN, Sevy JO, Brooks BD, Grainger DW, Brooks AE. Evaluating antibiotic release profiles as a function of polymer coating formulation. Biomed Sci Instrum. 2011;47: 46-51.
71. Shors EC. http://alfa-med. net/Pdfs/urun45. pdf.
72. Orthovita. The packing of vitoss synthetic cancellous bone void filler into bone defects 2000. http://www. ossano. se/Bibliotek/Vitoss/5606-0057(EU). pdf. Accessed 10 Nov 11.
73. Bloebaum RD, Bachus KN, Mitchell W, Hoffman G, Hofmann AA. Analysis of the bone surface area in resected tibia. Implications in tibial component subsidence and fixation. Clin Orthop Relat Res. 1994;309: 2-10.
74. Liu J, Xiao Y, Allen C. Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J Pharm Sci. 2004;93(1): 132-43.
75. Bordes C, Freville V, Ruffin E, Marote P, Gauvrit JY, Briancon S, et al. Determination of poly(epsilon-caprolactone) solubility parameters: application to solvent substitution in a microencapsulation process. Int J Pharm. 2010;383(1-2): 236-43.
76. Huang J, Lin K, Deanin R. Three-dimensional solubility parameters of poly(e-caprolactone). J Appl Polym Sci. 2006;100(3): 2002-9.
77. Chuang W, Jeng U, Sheu H, Hong P. Competition between phase separation and crystallization in a PCL/PEG polymer blend captured by synchronized SAXS, WAXS, and DSC. Macromol Res. 2006;14(1): 45-51.
78. Chuang W, Shih K, Hong P. Kinetics of phase separation in poly(ε-caprolactone)/poly(ethylene glycol) blends. Journal of Polymer Research. 2005;12(3).
79. Liu KL, Widjaja E, Huang Y, Ng XW, Loo SCJ, Boey FYC, et al. A new insight for an old system: protein-PEG colocalization in relation to protein release from PCL/PEG blends. Molecular Pharmaceutics. 2011;8(6): 2173-82.
80. Wu PL, Beerbower A, Martin A. Extended Hansen approach: calculating partial solubility parameters of solid solutes. J Pharm Sci. 1982;71(11): 1285-7.
81. Wan Y, Wu H, Yu A, Wen D. Biodegradable polylactide/chitosan blend membranes. Biomacromolecules. 2006;7(4): 1362-72.
82. Bramfeldt H, Sarazin P, Vermette P. Blends as a strategy towards tailored hydrolytic degradation of poly(ε-caprolactone-co-d, l-lactide)-poly(ethylene glycol)-poly(ε-caprolactone-co-d, l-lactide) co-polymers. Polym Degrad Stab. 2008;93(4): 877-82.
83. Neut D, van de Belt H, Stokroos I, van Horn JR, van der Mei HC, Busscher HJ. Biomaterial-associated infection of gentamicin-loaded PMMA beads in orthopaedic revision surgery. J Antimicrob Chemother. 2001;47(6): 885-91.
84. Levison ME, Knight R, Kaye D. In vitro evaluation of tobramycin, a new aminoglycoside antibiotic. Antimicrob Agents Chemother. 1972;1(5): 381-4.
85. Malinin TI, Carpenter EM, Temple HT. Particulate bone allograft incorporation in regeneration of osseous defects; importance of particle sizes. Open Orthop J. 2007;1: 19-24.